Zhang Yaping, Zhang Qun, Han Xingzhi, Han Lu, Wang Ting, Hu Jing, Li Li, Ding Zhou, Shi Xiao, Qian Xiaoping
The Comprehensive Cancer Center, Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical University, Nanjing 210008, China; Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing 210008, China.
Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing 210008, China.
Transl Oncol. 2023 May;31:101654. doi: 10.1016/j.tranon.2023.101654. Epub 2023 Mar 15.
Recently, immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1) monoclonal antibodies (mAbs), have revolutionized the treatment of malignant tumors. Therefore, the number of studies aiming to screen and identify new immune checkpoint molecules for antitumor immunotherapy is increasing. Signaling lymphocytic activation molecule (SLAM) family members are mainly expressed by and regulate the functions of immune cells. Recent studies have shown that several SLAM family members are involved in the regulation of the tumor immune microenvironment and are promising targets for antitumor immunotherapy. Signaling lymphocytic activation molecule family member 8 (SLAMF8) is a type I cell surface glycoprotein and is encoded on chromosome 1q21. To further illustrate the clinical value of SLAMF8 in colorectal cancer (CRC), we retrospectively analyzed the relationship between SLAMF8 expression and the prognosis of CRC patients and the associations between SLAMF8 expression and the expression levels of other SLAM family members and other classic immune checkpoint molecules using The Cancer Genome Atlas (TCGA) data, RNA sequencing data, tissue immunohistochemistry staining, and systematic follow-up analysis. Here, high SLAMF8 expression was associated with poor overall survival (OS) in CRC. The mRNA expression level of SLAMF8 was positively correlated with the expression levels of multiple classic immune checkpoints and other SLAM family members. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis suggested that the pathways enriched in CRC tissues with high SLAMF8 expression were associated with the regulation of the tumor immune microenvironment.
最近，免疫检查点抑制剂（ICIs），如程序性细胞死亡1（PD-1）单克隆抗体（mAbs），彻底改变了恶性肿瘤的治疗方式。因此，旨在筛选和鉴定用于抗肿瘤免疫治疗的新免疫检查点分子的研究数量正在增加。信号淋巴细胞激活分子（SLAM）家族成员主要由免疫细胞表达并调节其功能。最近的研究表明，几个SLAM家族成员参与肿瘤免疫微环境的调节，是抗肿瘤免疫治疗的有希望的靶点。信号淋巴细胞激活分子家族成员8（SLAMF8）是一种I型细胞表面糖蛋白，由1号染色体q21编码。为了进一步阐明SLAMF8在结直肠癌（CRC）中的临床价值，我们使用癌症基因组图谱（TCGA）数据、RNA测序数据、组织免疫组化染色和系统随访分析，回顾性分析了SLAMF8表达与CRC患者预后之间的关系，以及SLAMF8表达与其他SLAM家族成员和其他经典免疫检查点分子表达水平之间的关联。在此，高SLAMF8表达与CRC患者较差的总生存期（OS）相关。SLAMF8的mRNA表达水平与多个经典免疫检查点和其他SLAM家族成员的表达水平呈正相关。京都基因与基因组百科全书（KEGG）通路分析表明，高SLAMF8表达的CRC组织中富集的通路与肿瘤免疫微环境的调节有关。
